Avid Bioservices has completed upgrades to its manufacturing infrastructure and systems to meet increased demand for services and the potential commercialization of Peregrine's bavituximab and Cotara.
Avid has enhanced its Reverse Osmosis Deionized (RODI) and Water for Injection (WFI) systems, resulting in a 450% increase in water capacity to support increased production. Other projects include a contract with Advanced BioScience Laboratories to provide development and large-scale manufacturing services to support cGMP production of an HIV envelope protein.
"We have seen tremendous growth in the demand for services at Avid, based on both the success of our clients and the continued commitment to excellence by our dedicated team," said Steven W. King, president of Avid Bioservices. "We are strategically reinvesting some of these financial resources back into the business to further increase manufacturing throughput, reduce manufacturing risks and ensure continued reliability with redundant systems."
"This rollout of recent facility enhancements, as well as the plans for the next phases, requires timely, accurate and strategic execution across the organization. In completing this first phase ahead of schedule, teams from across the company worked together in unison to seamlessly implement these upgrades, while concurrently maintaining scheduled production, a reflection on the expertise and teamwork that we continually provide our clients," said Jeff Masten, vice president of quality for Avid Bioservices.